Watson Can Sell Generic Actos Now, U.S. Judge Rules

Watson Pharmaceuticals Inc. may begin immediately marketing a generic version of Takeda Pharmaceutical Inc.’s diabetes drug Actos, a federal judge ruled, handing the U.S. Food and Drug Administration a defeat.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.